Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-ADT: Interventions for Metabolic Protection Against Cardiometabolic Toxicity During ADT
NCT07202247Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Nov 2025
- Primary completion
- Apr 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide, tirzepatide in cardiovascular disease (CVD), sponsored by City of Hope. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT07202247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07202247.